Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ
Market Cap
$1.48B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
225 of 966
Rank in Industry
138 of 554
Largest Insider Buys in Sector
ARQT Stock Price History Chart
ARQT Stock Performance
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Activity of Arcutis Biotherapeutics, Inc.
Over the last 12 months, insiders at Arcutis Biotherapeutics, Inc. have bought $247,554 and sold $3.24M worth of Arcutis Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Arcutis Biotherapeutics, Inc. have bought $34.27M and sold $3.89M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $1.6M. Watanabe Todd Franklin (See Remarks) — $21,250. Matsuda Masaru (See Remark) — $18,543.
The last purchase of 1,093 shares for transaction amount of $7,767 was made by Edwards Larry Todd (See Remarks) on 2024‑11‑30.
List of Insider Buy and Sell Transactions, Arcutis Biotherapeutics, Inc.
| 2024-12-02 | Sale | director | 10,000 0.0086% | $12.51 | $125,133 | -0.52% | ||
| 2024-11-30 | See Remarks | 2,038 0.0009% | $7.11 | $14,482 | 0.00% | |||
| 2024-11-30 | See Remarks | 1,657 0.0008% | $7.11 | $11,775 | 0.00% | |||
| 2024-11-30 | See Remarks | 1,093 0.0005% | $7.11 | $7,767 | 0.00% | |||
| 2024-11-22 | Sale | See Remarks | 16,023 0.0136% | $10.14 | $162,515 | +21.40% | ||
| 2024-11-19 | Sale | See Remarks | 1,775 0.0015% | $9.68 | $17,190 | +4.70% | ||
| 2024-11-15 | Sale | See Remarks | 100 <0.0001% | $10.03 | $1,003 | +29.48% | ||
| 2024-11-14 | Sale | See Remarks | 18,377 0.0161% | $10.29 | $189,182 | 0.00% | ||
| 2024-11-11 | Sale | director | 8,687 0.0074% | $10.85 | $94,238 | +6.18% | ||
| 2024-11-04 | Sale | See Remarks | 13,871 0.0117% | $8.68 | $120,459 | +24.08% | ||
| 2024-11-04 | Sale | See Remarks | 15,441 0.0131% | $8.68 | $134,093 | +24.08% | ||
| 2024-11-04 | Sale | See Remarks | 5,015 0.0042% | $8.68 | $43,551 | +24.08% | ||
| 2024-11-01 | Sale | director | 10,000 0.0085% | $8.65 | $86,541 | +24.51% | ||
| 2024-10-02 | Sale | SVP Chief Commercial Officer | 3,725 0.0035% | $10.01 | $37,295 | -2.05% | ||
| 2024-10-01 | Sale | director | 10,000 0.0086% | $9.26 | $92,616 | +5.55% | ||
| 2024-09-24 | Sale | Chief Financial Officer | 11,626 0.0098% | $9.48 | $110,264 | -3.42% | ||
| 2024-09-03 | Sale | director | 10,000 0.0088% | $10.77 | $107,695 | -3.14% | ||
| 2024-08-19 | Sale | See Remarks | 1,728 0.0014% | $8.29 | $14,318 | +17.69% | ||
| 2024-08-02 | Sale | See Remarks | 14,487 0.0122% | $9.02 | $130,648 | +9.62% | ||
| 2024-08-02 | Sale | See Remarks | 13,206 0.0111% | $9.02 | $119,106 | +9.62% |
Insider Historical Profitability
2.91%
| Heron Patrick J | director | 8785284 7.5059% | $12.61 | 3 | 0 | <0.0001% |
| Watanabe Todd Franklin | See Remarks | 838430 0.7163% | $12.61 | 3 | 43 | +6.79% |
| Matsuda Masaru | See Remarks | 187030 0.1598% | $12.61 | 2 | 11 | |
| Welgus Howard G. | director | 161944 0.1384% | $12.61 | 0 | 35 | |
| Topper David Joseph | Chief Financial Officer | 158374 0.1353% | $12.61 | 0 | 1 | |
| Moore Matthew Richard | SVP and Chief Business Officer | 145505 0.1243% | $12.61 | 0 | 3 | |
| Edwards Larry Todd | See Remarks | 137728 0.1177% | $12.61 | 1 | 2 | |
| Burnett Patrick | See Remarks | 128669 0.1099% | $12.61 | 0 | 16 | |
| Curran Terrie | director | 10139 0.0087% | $12.61 | 0 | 1 | |
| Frazier Life Sciences VIII, L.P. | 10 percent owner | 8764232 7.4879% | $12.61 | 2 | 0 | +5.03% |
| ORBIMED ADVISORS LLC | 4267564 3.6461% | $12.61 | 2 | 0 | +10.62% | |
| SILVERSTEIN JONATHAN | 4267564 3.6461% | $12.61 | 2 | 0 | +10.62% | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 3979292 3.3998% | $12.61 | 1 | 0 | +5.03% |
| CHAUDHURI BHASKAR | director | 841391 0.7189% | $12.61 | 0 | 9 | |
| OrbiMed Capital GP VII LLC | 415142 0.3547% | $12.61 | 0 | 2 | ||
| OSBORNE DAVID W | Chief Technical Officer | 268854 0.2297% | $12.61 | 0 | 10 | |
| Lock Kenneth A. | Chief Commercial Officer | 63429 0.0542% | $12.61 | 0 | 6 | |
| Turney Patricia A. | SVP, Operations | 62862 0.0537% | $12.61 | 0 | 6 | |
| Burrows Scott L | Chief Financial Officer | 59115 0.0505% | $12.61 | 0 | 6 | |
| Smither John W | Chief Financial Officer | 46321 0.0396% | $12.61 | 0 | 7 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| JENNISON ASSOCIATES LLC | $120.67M | 10.52 | 12.18M | +34.31% | +$30.82M | 0.08 | |
| Frazier Life Sciences Management L P | $87.06M | 7.59 | 8.79M | +0.24% | +$208,625.32 | 3.93 | |
| State Street | $87.05M | 7.59 | 8.78M | +475.99% | +$71.94M | <0.01 | |
| Suvretta Capital Management, LLC | $78.06M | 6.81 | 7.88M | -7.03% | -$5.9M | 3.3 | |
| Helm Capital Management LLC | $74.42M | 6.49 | 7.51M | +13.03% | +$8.58M | 2.2 | |
| Polar Capital | $68.24M | 5.95 | 6.89M | +9.34% | +$5.83M | 0.38 | |
| BlackRock | $65.99M | 5.75 | 6.66M | +12.54% | +$7.36M | <0.01 | |
| The Vanguard Group | $51.2M | 4.46 | 5.17M | +5.51% | +$2.67M | <0.01 | |
| Franklin Templeton Investments | $46.01M | 4.01 | 4.64M | -0.28% | -$129,662.44 | 0.01 | |
| Gilder Gagnon Howe & Co. LLC | $41.97M | 3.66 | 4.23M | New | +$41.97M | 0.54 | |
| Morgan Stanley | $39.7M | 3.46 | 4.01M | -34.14% | -$20.58M | <0.01 | |
| Ensign Peak Advisors Inc | $29.54M | 2.57 | 2.98M | +46.82% | +$9.42M | 0.05 | |
| Cormorant Asset Management Lp | $21.06M | 1.84 | 2.13M | New | +$21.06M | 0.98 | |
| Pivotal Bioventure Partners Investment Advisor Llc | $20.1M | 1.75 | 2.03M | +6.18% | +$1.17M | 16.16 | |
| Bain Capital Life Sciences Investors Llc | $19.94M | 1.74 | 2.01M | -32.94% | -$9.79M | 1.6 | |
| Geode Capital Management | $19.54M | 1.7 | 1.97M | +13.07% | +$2.26M | <0.01 | |
| Citadel Advisors LLC | $18.97M | 1.65 | 1.91M | New | +$18.97M | 0.01 | |
| Deutsche Bank | $18.56M | 1.62 | 1.87M | +34.29% | +$4.74M | 0.01 | |
| Farallon Capital | $17.64M | 1.54 | 1.78M | New | +$17.64M | 0.12 | |
| GW&K Investment Management | $17.06M | 1.49 | 1.72M | +4.93% | +$801,967.46 | 0.15 | |
| J. Goldman & Company | $14.22M | 1.24 | 1.44M | +755.72% | +$12.56M | 0.49 | |
| Braidwell Lp | $12.88M | 1.12 | 1.3M | New | +$12.88M | 0.73 | |
| American Century Investments | $10.32M | 0.9 | 1.04M | +14.16% | +$1.28M | 0.01 | |
| JPMorgan Chase | $9.91M | 0.86 | 1M | +1,299.58% | +$9.2M | <0.01 | |
| Voloridge Investment Management, LLC | $9.35M | 0.82 | 943,467 | New | +$9.35M | 0.03 | |
| Tejara Capital Ltd | $9.32M | 0.81 | 940,487 | -15.44% | -$1.7M | 3.16 | |
| Invesco | $8.64M | 0.75 | 872,344 | +3,370.5% | +$8.4M | <0.01 | |
| Bank of America | $8.43M | 0.74 | 850,529 | +834.46% | +$7.53M | <0.01 | |
| Rafferty Asset Management Llc | $8.15M | 0.71 | 822,461 | New | +$8.15M | 0.02 | |
| Kairos Capital Management Lp | $8.02M | 0.7 | 809,332 | New | +$8.02M | 3.84 | |
| Goldman Sachs | $7.99M | 0.7 | 806,524 | +10.03% | +$728,603.04 | <0.01 | |
| Balyasny Asset Management Llc | $7.74M | 0.67 | 780,780 | New | +$7.74M | 0.02 | |
| Perceptive Advisors | $7.43M | 0.65 | 750,000 | New | +$7.43M | 0.01 | |
| Charles Schwab | $7.44M | 0.65 | 750,724 | +31.4% | +$1.78M | <0.01 | |
| Northern Trust | $7.42M | 0.65 | 748,945 | +2.49% | +$180,371.93 | <0.01 | |
| Prudential Financial | $7.17M | 0.63 | 723,325 | -11.58% | -$938,774.33 | 0.01 | |
| Citigroup | $7.1M | 0.62 | 716,440 | +5,535.49% | +$6.97M | 0.01 | |
| Sio Capital Management LLC | $6.3M | 0.55 | 635,969 | 0% | +$0 | 2.27 | |
| Ikarian Capital LLC | $5.84M | 0.51 | 589,642 | New | +$5.84M | 0.8 | |
| HSBC | $5.01M | 0.44 | 506,286 | +251.75% | +$3.58M | <0.01 | |
| Ecor1 Capital Llc | $4.96M | 0.43 | 500,000 | New | +$4.96M | 0.04 | |
| UBS | $4.86M | 0.42 | 490,677 | +23,265.57% | +$4.84M | <0.01 | |
| Two Sigma | $4.8M | 0.42 | 484,081 | -50.54% | -$4.9M | 0.01 | |
| Tri Locum Partners Lp | $4.46M | 0.39 | 449,694 | New | +$4.46M | 0.37 | |
| Monashee Investment Management LLC | $3.77M | 0.33 | 380,000 | New | +$3.77M | 0.32 | |
| Millennium Management LLC | $3.76M | 0.33 | 379,051 | -85.19% | -$21.6M | <0.01 | |
| Trexquant Investment LP | $3.6M | 0.31 | 362,869 | New | +$3.6M | 0.06 | |
| Federated Hermes | $3.47M | 0.3 | 350,114 | -32.86% | -$1.7M | 0.01 | |
| AMI Asset Management Corp. | $3.42M | 0.3 | 345,239 | New | +$3.42M | 0.18 | |
| Two Sigma Advisers LP | $3.28M | 0.29 | 330,900 | New | +$3.28M | 0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.